
March 3 (Reuters) - Fresenius Medical Care AG FMEG.DE:
FRESENIUS KABI: OTULFI WILL BE AVAILABLE IN U.S. SOME PRESENTATIONS
FRESENIUS KABI: OTULFI IN 45 MG/0.5 ML SINGLE-DOSE VIAL FOR SUBCUTANEOUS INJECTION IS EXPECTED TO RECEIVE FDA APPROVAL IN H1 2025
Source text: ID:nBw2yxSBza
Further company coverage: FMEG.DE